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Introduction.Thepurposeofthisstudywastoevaluatetheroleofrenalcryoablationinpatientswithsolitarykidneyswiththegoals
of tumor destruction and maximal renal parenchymal preservation. Methods. Eleven patients with single tumors were treated with
cryoablation, of which 10 patients had solitary kidneys and 1 had a nonfunctioning contralateral kidney. All procedures were
performed via an open extraperitoneal approach; ten tumors were treated with in-situ cryoablation and 1 tumor was treated
with cryo-assisted partial nephrectomy. Results. Cryoablation was successfully performed without any preoperative complications.
Meanpatientagewas62.4years(range49–79),tumorlocationincluded:6(upperpole),2(mid-kidney),3(lowerpole).Themean
and median tumor size was 2.6cm and 2.8cm (range 1.2–4.3cm), mean operative time 205 minutes (range 180–270 minutes),
blood loss 98.5ml (range 40–250ml), and hospitalization 4.6 days (range 3–8 days). Creatinine values included: preoperative
1.43mg/dL (range 1.2–1.9), postoperative 1.67mg/dL (range 1.5–2.5), and nadir 1.57mg/dL (range 1.3–2.1). All patients were
followed postoperatively with magnetic resonance imaging for surveillance. At a median follow-up of 43 months, 9 patients
had no evidence of recurrence, 1 patient has an enhancing indeterminate area, and 1 patient was lost to follow-up. Conclusion.
Intermediate-term results suggest that renal cryoablation oﬀers a feasible alternative for patients that require a maximal nephron-
sparing eﬀort with preservation of renal function and minimal risk of tumor recurrence.
Copyright © 2008 Ravi Munver et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Nephron-sparing surgery (NSS) entails complete resection
or destruction of a renal tumor while maximizing preserva-
tionofnormalparenchymaltissue.Improvementsinsurgical
techniques have gradually led to more widespread utiliza-
tion of partial nephrectomy with acceptable postoperative
morbidity and equivalent oncologic eﬃcacy as compared
to radical nephrectomy. Cryoablation is an alternative to
partial nephrectomy for the treatment of renal tumors and
it employs the concept of nephron-sparing surgery [1, 2].
The purpose of this study was to evaluate cryoablation as
an NSS technique for the treatment of small renal masses in
patients with solitary kidneys. We reviewed the application,
eﬀect on renal function, and intermediate outcomes of
cryoablation in this subset of patients that require maximal
renal parenchyma preservation while fulﬁlling the goal of
tumor destruction.
2. MATERIALS AND METHODS
Between August 2000 and November 2004, 11 patients (9
male, 2 female) were treated with renal cryoablation for
suspicious renal lesions. All patients had a single renal
mass suspicious for malignancy based on radiologic imaging
studies. Ten patients had a solitary kidney and 1 had a non-
functioning contralateral kidney. Cryoablation was selected2 Advances in Urology
Figure 1: Open renal cryoablation. Cryoprobe with 2 temperature
probes are seen.
in order to oﬀer patients a nephron-sparing procedure in
cases that, due to tumor location, were not ammenable to
partial nephrectomy. Patients did not receive preoperative
biopsy of the renal mass lesion due to the associated risk of
bleeding and renal injury in patients with solitary kidneys.
Ten tumors were treated with insitu cryoablation and 1
tumor was treated with cryoassisted partial nephrectomy.
An extraperitoneal ﬂank incision was made between the
10th and 11th ribs allowing exposure of the kidney and renal
tumor. Intraoperative high-resolution renal ultrasonography
with a 7.5MHz transducer was used to establish and conﬁrm
tumor size, depth of invasion, and proximity to the renal
hilar vessels and the collecting system. The renal hilar vessels
were isolated but not occluded in all cases. Each tumor was
biopsied with a 14gauge Tru-Cut needle prior to initiation of
cyroablation.
Cryoablation was performed using the Cryocare surgical
system(EndocareInc.,Irvine,Calif,USA).Underultrasound
guidance, 1 or 2 cryoprobes were placed directly into the
identiﬁed lesion, and temperature sensor probes were placed
at the periphery of each mass to provide intraoperative mon-
itoring of adjacent renal parenchymal temperatures. In each
case, the tumor margins were localized with intraoperative
ultrasound,allowingforpreciseplacementofthecryoprobes.
After cryoprobe placement, the tumor was treated with 2
freeze cycles (−40C
◦ for 10–15 minutes/cycle) (see Figure 1).
Each freeze cycle was followed by an active thaw process. In
the case of the partial nephrectomy, the tumor was excised
with a scalpel by tracing the edge of the ice ball.
Perioperative data were evaluated including tumor size,
operative time, estimated blood loss, length of hospital stay,
and preoperative and postoperative creatinine.
3. RESULTS
Eleven patients were treated with cryoablation for 5 right
renal tumors and 6 left renal tumors. The mean patient age
was 62.4 years (range 49–79 years). Tumors were located
in the upper pole (n = 6), mid-kidney (n = 2), and
lower pole (n = 3) with a mean and median tumor
size of 2.6cm and 2.8cm, respectively (range 1.2–4.3cm).
The mean operative time was 205 minutes (range 180–
270 minutes), blood loss 98.5mL (range 40–250mL), and
hospitalization 4.6 days (range 3–8 days). The procedure
was successfully completed in all patients without any major
intraoperative or postoperative complications.
Biopsies of the 11 lesions conﬁrmed renal cell carcinoma
(n = 7), oncocytoma (n = 2), and angiomyolipoma (n =
1), with one biopsy specimen that was indeterminate. The
patientthatunderwentcryoassistedpartialnephrectomyhad
negative margins.
The mean preoperative creatinine was 1.43 mg/dL (range
1.2–1.9) and postoperative creatinine was 1.67mg/dL (range
1.5–2.5). The nadir creatinine was 1.57mg/dL (range 1.3–
2.1). All patients were followed postoperatively with mag-
netic resonance imaging (MRI) at 3–6 month intervals.
Imaging these patients within the ﬁrst 3 months was not
performed due to our prior experience with inﬂammatory
responses in the treated area that can lead to misinterpreta-
tion. At a median follow-up of 43 months (4–59 months),
9 patients had no evidence of recurrence, 1 patient had an
indeterminate area, and 1 patient was lost to follow-up after
4 months.
4. DISCUSSION
Cryoablation is a minimally invasive technique that has
emerged as an option for small renal masses with reduced
morbidity compared to partial nephrectomy. This technol-
ogy provides a nephron-sparing alternative that is curative
by destruction rather than excision of the renal mass [3].
Tissue destruction from cryoablative therapy occurs
from sequential freezing and thawing of tissues. Cellular
destruction from the freeze process results from complex
direct and indirect physiologic mechanisms, including direct
physical disruption of the cellular membranes, proteins,
and intracellular organelles from ice crystals. In addition,
there are indirect eﬀects such as microvascular thrombosis,
osmotic dehydration, and cellular anoxia during the freeze
process, which may also extend beyond the physical ice
ball. The initial histologic change noted after a cryoablative
procedure is coagulative necrosis. Subsequently, chronic
ﬁbrosis with collagen deposition results [2].
Early animal studies by Nakada et al. utilizing and in
vivo rabbit renal cell cancer tumor model demonstrated that
thermosensor-monitored renal cryosurgery produces similar
outcomes to nephrectomy in terms of preventing metastatic
disease [4]. Rodriguez et al. published preliminary results of
series of seven patients undergoing renal cryoablation [5].
The estimated blood loss averaged 111mL and there were
no perioperative complications. Six of the 7 patients had
a minimum of one follow-up computed tomography scan
(mean follow-up of 14.2 months) and each of these studies
demonstrated partial resolution of the lesion.
Rukstalis et al. reviewed a cohort of 29 patients that were
treated with open renal cryoablation since 1996 [6]. The
median preoperative renal mass size was 2.2cm, of which
22 were solid renal masses and 7 were complex renal lesions.Ravi Munver et al. 3
Five major adverse events occurred of which only one event
was directly related to the procedure. At median follow-
up of 16 months, 1 patient experienced a biopsy-proven
local recurrence, and 91.3% of patients had a complete
radiographic response with only a residual scar or small
nonenhancing cyst. The authors concluded that open renal
cryoablation appeared safe for the destruction of solid or
complex renal masses, although rigorous radiographic, and
clinical follow-up was required.
Chen et al. reported their experience with laparoscopic
cryoablation of renal masses in 35 patients that underwent
successfultherapywithminimalpostoperativecomplications
[7]. In their series, the mean operative time was 3 hours
and mean estimated blood loss was 85mL. At 11 months of
follow-up,therewerenolocalorportsitetumorrecurrences.
In a similar study by Gill et al., 32 patients underwent
laparoscopic renal cryoablation. In this study, there were no
local tumor recurrences in this group of patients [8].
Cryoablation is becoming an increasingly popular mini-
mallyinvasivetechniquefortreatingrenalcellcarcinomaand
has been shown to eﬀectively treat renal and adrenal masses
[8, 9]. This technique appears to be safe and eﬃcacious, with
recurrence rate reported as low as 6.7%, and a 5year cancer-
speciﬁc survival rate of 100% for RCC [10–12].
Patients with solitary kidneys or impaired renal function
may beneﬁt from renal cryoablation as compared to partial
nephrectomy for several reasons. Cryoablation may be
associated with a lower risk for bleeding and may obviate
the need for hilar occlusion, thus preventing the detrimental
eﬀects related to controlled ischemia. Our patients that were
considered to be appropriate candidates for cryoablation
did not require hilar occlusion of their solitary renal unit.
While partial nephrectomy can be selectively performed
without warm ischemia, the patients in our series had tumor
characteristics that were not optimal for this procedure
without hilar occlusion.
In our early experience with cryoablation for patients
with solitary kidneys, each patient underwent an open pro-
cedure in order to minimize inadvertent injury and conﬁrm
adequate placement of the cryoprobes. Since our initial
experience, we have continued our eﬀorts to further decrease
morbidity by transitioning to a laparoscopic approach for
suitable tumors in this cohort of patients.
Intraoperativeultrasoundwasessentialindelineatingthe
intrarenal anatomy and the dimensions of the tumor [13].
Moreover, ultrasonography allows visualization of the ice
ball to conﬁrm adequate treatment of the entire lesion. In
the patient that underwent cryoassisted partial nephrectomy,
the tumor was excised following the freeze cycle with the
intention of minimizing blood loss, as hilar occlusion was
not employed. Utilization of the edge of the ice ball served as
a guide for resection and facilitated complete excision of the
mass with minimal blood loss.
Renal cryoablation has been reported to target kidney
tumors in a precise, safe, and reproducible manner. This
technology oﬀers the ability to treat renal tumors in patients
that require a maximal parenchymal sparing procedure,
such as patients with solitary kidneys. Renal cryoablation
allows the accurate and safe application of this surgical
modality for the treatment of renal tumors with emphasis
on parenchymal sparing. Additionally, the need for hilar
occlusion of a solitary renal unit is completely obviated. Our
intermediate follow-up data is promising in terms of both
cancer control and preservation of renal function. We do
not routinely perform renal biopsies following cryoablation
due to the associated risks of bleeding and renal injury in
patients with solitary kidneys. Instead, this practice can be
reserved for patients with a suspicious enhancing area on
follow-up surveillance imaging studies. If a positive biopsy
is obtained in this instance, the options for surveillance,
repeatcryoablation,ornephrectomymaybeconsidered.Our
results are consistent with other reports in the literature and
demonstrate that renal cryoablation is a feasible technique
for the management of small renal masses in patients with
solitary kidneys. Additionally, combined with a laparoscopic
approach, cryoablation is an attractive minimally invasive
treatment option in such patients.
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